Non-GAAP diluted earnings per share for the quarter were $1.21, an increase of 21% over the prior year quarter while GAAP diluted earnings per share for the quarter were $1.10.
We continue to deliver operating leverage with non-GAAP operating profit growth of 21% year-over-year and non-GAAP diluted earnings per share of $1.21.
Excluding the impact of this gain, our non-GAAP earnings per share would have been $1.07.
Group revenue for the December quarter was $736 million, an increase of 13% over the prior year quarter.
Sales in Europe, Asia and other markets totaled $242 million, an increase of 5% over the prior year quarter.
Our SaaS portfolio revenue grew 37% year-on-year this last quarter, benefiting from the MatrixCare acquisition that we lapped during November.
Revenue in Europe, Asia and other markets device sales were $162 million, an increase of 4% over the prior year quarter or in constant currency terms, an increase of 6%.
We were up 14% in constant currency across our portfolio.
Software as a service revenue for the second quarter was $87 million, an increase of 37% over the prior year quarter.
Looking forward, subject to currency movements and taking into account recent acquisitions, we expect SG&A as a percentage of revenue to be in the range of 23% to 25% for the remaining two quarters of fiscal year 2020.
Our total assets were $4.4 billion and our balance sheet remains strong with modest debt levels.
Masks and other sales were $204 million, an increase of 19% over the prior year quarter.
Looking forward, subject to currency movements, we expect R&D expenses as a percentage of revenue to be in the range of 7% to 8% for the balance of fiscal year 2020.
It took around 24 months to see strong sustainable returns from our investments in R&D and our management team at Brightree.
Taking a closer look at our geographic distribution and excluding revenue from our software as a service business, our sales in U.S., Canada and Latin America countries were $408 million, an increase of 14% over the prior year quarter.
Masks and other sales in Europe, Asia and other markets were $79 million, an increase of 8% over the prior year quarter or in constant currency terms, an increase of 11%.